News
Structure Therapeutics Inc. Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks. Comprehensive development program also includes Phase 2 ACCESS II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback